Lv11
62 积分 2021-05-26 加入
Fifty years of monoclonals: the past, present and future of antibody therapeutics
13分钟前
待确认
The anti-inflammatory activity of IgG is enhanced by co-engagement of type I and II Fc receptors
23分钟前
已完结
CRISPR technology: A decade of genome editing is only the beginning
2个月前
已完结
CRISPR technologies for genome, epigenome and transcriptome editing
2个月前
已完结
A tumor-conditional IL-15 safely synergizes with immunotherapy to enhance antitumor immune responses
11个月前
已完结
A survey of FDA Approved Monoclonal Antibodies and Fc-fusion Proteins for Manufacturing Changes and Comparability Assessment
1年前
已完结
The present and future of bispecific antibodies for cancer therapy
1年前
已完结
Antibody variable region engineering for improving cancer immunotherapy
3年前
已完结
An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity
3年前
已完结
Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity
4年前
已完结
Long-term outcome after allogeneic stem cell transplantation in multiple myeloma
4年前
已采纳
Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study
4年前
已采纳
皖公网安备34019202002308
